Navigation Links
Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
Date:6/4/2013

CAMBRIDGE, Mass., June 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be combined with standard doses of certain cytotoxic agents  for investigation as treatment for patients with advanced solid tumors. The research was presented at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, May 31 – June 4, 2013.

The Phase 1 study of 43 patients with advanced solid tumors established that MM-121 can be combined at its recommended single agent dose with gemcitabine, pemetrexed, cabazitaxel or carboplatin.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival across multiple malignancies. Preclinical research in several model systems has shown that by inhibiting ErbB3 signaling, MM-121 may restore sensitivity, delay resistance and enhance the effect of certain cytotoxic agents as a combination therapy.

"These data serve as the foundation for moving MM-121 into potential Phase 2 studies in combination with these chemotherapy agents in certain tumor types," said Akos Czibere , MD, Ph.D., Senior Medical Director of the MM-121 program at Merrimack. "MM-121 has the potential to complement the impact of several existing standard-of-care therapies and we look forward to further exploring its promise."

Sanofi and Merrimack entered into an exclusive, global license and collaboration agreement for MM-121 in 2009.

Study Methodology & Results

Abstract Number: 2609
Abstract Title: A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced soli
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
2. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
5. Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
6. Ferring Pharmaceuticals Inc. Announces $1M Donation to the Alliance for Fertility Preservation, a Newly Formed Charitable Organization
7. Ampio Pharmaceuticals Provides Clinical Updates
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
10. Isis Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
11. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... According to a new market research report ... Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, Diagnosis, ... Global Forecast to 2020", published by MarketsandMarkets, the total ... $56.50 Billion by 2020, growing at a CAGR of ... market data Tables and 71 Figures spread through 312 ...
(Date:9/17/2014)... , Sept. 17, 2014 An analysis ... regarding patients taking Sovaldi® (sofosbuvir), a new and expensive ... shows that over the last several months (May through ... downward trend in Sovaldi utilization. This suggests another surge ... new therapeutic regimens of similar efficacy and shorter duration ...
(Date:9/17/2014)... MORRISTOWN, N.J. , Sept. 17, 2014 /PRNewswire/ ... LLP (MDM&C), today announced that it will serve ... the Benefits and Avoiding the Risks of Healthcare ... 2014 that will examine delivery systems, reimbursement, compliance ... Affordable Care Act. Logo -  ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... Conn., Sept 18 Further results from the initial clinical trial ... for varicose veins, will be delivered on Friday, September 25, at ... The device combines mechanical and chemical modalities to accomplish vein treatment ... Steve Elias MD FACS FACPh, Associate Professor of Surgery at Mount ...
... NEWNAN, Ga., Sept. 16 CeloNova BioSciences, Inc. today announced ... the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) conference ... treating liver cancer. Professor Orsi and his colleagues at the ... technique to cut off the blood supply inside liver tumors ...
Cached Medicine Technology:ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented 2New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal 2
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that provides many kinds ... released its 2014 empire waist evening dress ... big sale for these new and beautiful products. All ... from 15 to 65 percent off. , It ... to wear materials. Its elegant items include gold empire ...
(Date:9/17/2014)... September 18, 2014 IntimateRider, an inventor ... adults , has announced that it has entered into ... & Mobility LLC. A primary reason for the deal ... distribution reach is global. About its sales potential, representatives ... to provide you with the latest products on the ...
(Date:9/17/2014)... September 18, 2014 iFitDress.com, a renowned wedding ... of petite evening dresses . All these outfits are ... and discounted shipping costs. , ā€œiFitDress.com is a professional ... gowns. We are now busy selling our new collection of ... place an order above $800 can get free shipping. All ...
(Date:9/17/2014)... September 18, 2014 The National Resident ... Match , a comprehensive analysis of the relationship between ... preferred specialty. The new edition is based on ... specialty for U.S. allopathic medical school senior students and ... be able to provide this new edition of Charting ...
(Date:9/17/2014)... Columbus, Ohio (PRWEB) September 18, 2014 ... cycle management services nationwide, announces today that they ... Fort Wayne Radiology (FWRadiology) in Fort Wayne, Indiana. ... range of billing services encompassing their proprietary suite ... Technology (EBT). EBT improves radiology billing and ...
Breaking Medicine News(10 mins):Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3Health News:Elegant Petite Evening Dresses Introduced By Renowned Supplier iFitDress.com 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3
... ... 10 NBTY, Inc. (NYSE: NTY ) ( www.NBTY.com ), a ... President and Chief Financial Officer will be interviewed live on FOXBusiness.com LIVE on ... www.foxbusiness.com/live on Friday, December 11, 2009 between 12 and ...
... , ... know much about depression , but are highly aware of ... by the National Alliance on Mental Illness (NAMI). ... Web site that includes resources for people of diverse communities. , ...
... that tuberculosis bacteria use to coerce disease-fighting cells to ... line the airways and other surfaces to protect and ... into helping create tubercles: the small, rounded masses characteristic ... their numbers and spread to other locations. ...
... ... Laser-type device to be coupled with Stem Cell Therapy in Novel ... San Diego (PRWEB) December 10, 2009 -- Entest Biomedical Inc. ... with Advanced Light Devices to develop a proprietary laser system. It is anticipated this investigational medical device will ...
... , New report notes that ... could decline by 36 percent , Oak Brook, Ill., ... (ASGE) lauds the recent news of the decline in U.S. colorectal ... that from 1975 to 2000, incidence rates dropped 22 percent and ...
... alcoholic beverages (at least three to four drinks per week, ... 30 percent increased risk of breast cancer recurrence, according to ... be most susceptible to the effects of alcohol on recurrence, ... this study will be presented December 9-13 at the Cancer ...
Cached Medicine News:Health News:NBTY to be Featured on the FOX Business Program FOXBusiness.com LIVE 2Health News:Depression Survey: Implications for Diverse Communities 2Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 2Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 3Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 2Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 3Health News:ASGE Lauds Drop in Colorectal Cancer Deaths 2Health News:ASGE Lauds Drop in Colorectal Cancer Deaths 3Health News:ASGE Lauds Drop in Colorectal Cancer Deaths 4Health News:Alcohol consumption may increase breast cancer recurrence risk 2
... The Venus-i Laser System is a ... laser system with applications in dermatology, cosmetic ... ophthalmology. An ideal laser for skin resurfacing, ... most powerful, Erbium:YAG lasers on the market. ...
... Laser System is a new, portable, light ... applications in dermatology, cosmetic and plastic surgery, ... laser for skin resurfacing, it is the ... lasers on the market. It provides an ...
... biolitecs Ceralas D 980 nm diode ... clean, bloodless field for most surgical procedures. ... D cuts optically without collateral tissue ... laser coagulates blood instantly and seals small ...
... The APTIMA COMBO 2 Assay is ... that uses target capture for in vitro ... CT and GC. The assay uses a ... capture (TC), Transcription-Mediated Amplification (TMA) and Dual ...
Medicine Products: